[go: up one dir, main page]

MX2022011671A - Vacunas contra el coronavirus y metodos de uso. - Google Patents

Vacunas contra el coronavirus y metodos de uso.

Info

Publication number
MX2022011671A
MX2022011671A MX2022011671A MX2022011671A MX2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A MX 2022011671 A MX2022011671 A MX 2022011671A
Authority
MX
Mexico
Prior art keywords
methods
vaccines against
against coronavirus
coronavirus
vaccines
Prior art date
Application number
MX2022011671A
Other languages
English (en)
Inventor
Ugur Sahin
Richard B Gaynor
Lakshmi Srinivasan
Asaf Poran
Dewi Harjanto
Christina Kuksin
Daniel Abram Rothenberg
John Srouji
Original Assignee
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNTech SE filed Critical BioNTech SE
Publication of MX2022011671A publication Critical patent/MX2022011671A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composiciones y métodos para la prevención y/o el tratamiento de una infección viral, en particular de la familia Coronaviridae.
MX2022011671A 2020-03-20 2021-03-19 Vacunas contra el coronavirus y metodos de uso. MX2022011671A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202062992666P 2020-03-20 2020-03-20
US202063026559P 2020-05-18 2020-05-18
US202063059582P 2020-07-31 2020-07-31
US202063086519P 2020-10-01 2020-10-01
US202063122904P 2020-12-08 2020-12-08
PCT/US2021/023267 WO2021188969A2 (en) 2020-03-20 2021-03-19 Coronavirus vaccines and methods of use

Publications (1)

Publication Number Publication Date
MX2022011671A true MX2022011671A (es) 2023-01-24

Family

ID=77771752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011671A MX2022011671A (es) 2020-03-20 2021-03-19 Vacunas contra el coronavirus y metodos de uso.

Country Status (11)

Country Link
US (2) US20230141371A1 (es)
EP (1) EP4121104A4 (es)
JP (1) JP2023518821A (es)
KR (1) KR20230004508A (es)
AU (1) AU2021237720A1 (es)
BR (1) BR112022018819A2 (es)
CA (1) CA3172315A1 (es)
IL (1) IL296617A (es)
MX (1) MX2022011671A (es)
TW (1) TW202200199A (es)
WO (1) WO2021188969A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230184764A1 (en) * 2020-04-06 2023-06-15 The Trustees Of Columbia University In The City Of New York Peptide sequences for detection and differentiation of antibody responses to sars-cov-2 and other human corona viruses
US20240269266A1 (en) * 2020-04-14 2024-08-15 The Regents Of The University Of California Broad-spectrum multi-antigen pan-coronavirus vaccine
CN113521268A (zh) 2020-04-22 2021-10-22 生物技术Rna制药有限公司 冠状病毒疫苗
WO2021243219A1 (en) * 2020-05-29 2021-12-02 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Adenovirus-based sars-cov-2 vaccine
CN116157411A (zh) * 2020-07-31 2023-05-23 东亚合成株式会社 SARS-CoV-2衍生氨基酸序列及其应用
US12247978B2 (en) * 2020-08-05 2025-03-11 Arizona Board Of Regents On Behalf Of Northern Arizona University Compositions and methods for detection and treatment of coronavirus infection
TWI884296B (zh) * 2020-08-11 2025-05-21 美商碩騰服務公司 抗冠狀病毒疫苗
CN112029781B (zh) * 2020-08-14 2023-01-03 中山大学 一种新型冠状病毒SARS-CoV-2的安全型复制子系统及其应用
US12419948B2 (en) * 2020-08-31 2025-09-23 The Broad Institute, Inc. Immunogenic compositions and use thereof
US20230287090A1 (en) * 2020-09-02 2023-09-14 The Feinstein Institutes For Medical Research USE OF SARS-CoV-2 RECEPTOR BINDING MOTIF (RBM)-REACTIVE MONOCLONAL ANTIBODIES TO TREAT COVID-19
AU2021323389B1 (en) * 2020-11-12 2022-03-24 Ahs Hospital Corp. SARS-CoV-2 immunodominant peptide constructs and uses thereof
JP7598538B2 (ja) * 2021-01-29 2024-12-12 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用
WO2022178591A1 (en) * 2021-02-24 2022-09-01 Biotome Pty Ltd Peptides and their use in diagnosis of sars-cov-2 infection
US20220356212A1 (en) * 2021-03-26 2022-11-10 Nanogen Pharmaceutical Biotechnology JSC Modified spike protein and method of treatment
EP4070814A1 (en) * 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
EP4319803B1 (en) 2021-04-08 2025-11-26 Vaxthera SAS Coronavirus vaccine comprising a mosaic protein
US20240409587A1 (en) * 2021-04-12 2024-12-12 La Jolla Institute For Immunology Coronavirus T Cell Epitopes and Uses Thereof
WO2022268916A2 (en) * 2021-06-23 2022-12-29 Ose Immunotherapeutics Pan-coronavirus peptide vaccine
WO2023044542A1 (en) * 2021-09-24 2023-03-30 The University Of Adelaide Sars cov-2 vaccine
WO2023049983A1 (en) * 2021-09-28 2023-04-06 Medicago Inc. Cpmv vlps displaying sars-cov-2 epitopes
CN113981140B (zh) * 2021-10-09 2024-02-27 广州达安基因股份有限公司 新型冠状病毒德尔塔突变株的检测方法及核酸检测试剂盒
EP4419136A1 (en) * 2021-10-21 2024-08-28 BioNTech SE Coronavirus vaccine
US20250295755A1 (en) 2021-10-22 2025-09-25 Sail Biomedicines, Inc. Mrna vaccine composition
AU2022374004A1 (en) 2021-10-22 2024-05-02 BioNTech SE Compositions for administration of different doses of rna
US20230203604A1 (en) * 2021-11-23 2023-06-29 nference, inc. Detection of covid-19 associated cardiac injury and vaccine-associated myocarditis
AU2022398450A1 (en) 2021-11-23 2024-06-06 Sail Biomedicines, Inc. A bacteria-derived lipid composition and use thereof
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
CN118647391A (zh) * 2021-12-08 2024-09-13 安达生物药物开发(深圳)有限公司 抗原性多肽及其用途
CA3241014A1 (en) 2021-12-20 2023-06-29 Munir MOSAHEB Mrna therapeutic compositions
CN114686620B (zh) * 2022-01-21 2024-05-07 生物岛实验室 新型冠状病毒多种变异株核酸质谱检测的引物组合、试剂盒及检测方法
AU2022369834A1 (en) 2022-01-27 2023-08-10 Shenzhen Rhegen Biotechnology Co., Ltd. SARS-CoV-2 mRNA Vaccine and Preparation Method and Use Thereof
JP2025504887A (ja) * 2022-01-28 2025-02-19 ファイザー・インク コロナウイルス抗原バリアント
WO2023147092A2 (en) * 2022-01-28 2023-08-03 BioNTech SE Coronavirus vaccine
CA3250246A1 (en) * 2022-02-08 2023-08-17 Iowa State University Research Foundation, Inc. RNA EXPRESSION AND ADMINISTRATION SYSTEMS
GB202201768D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Peptides
CN119136827A (zh) * 2022-03-02 2024-12-13 Isr免疫系统调节控股公共有限公司 包含抗原和tlr3激动剂的疫苗组合物
CN116768988A (zh) * 2022-03-09 2023-09-19 中生复诺健生物科技(上海)有限公司 编码新型冠状病毒S蛋白的mRNA疫苗
CN114907453B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的S蛋白多肽
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
CN114907454A (zh) * 2022-04-08 2022-08-16 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的N蛋白多肽
CN119255818A (zh) 2022-05-05 2025-01-03 伊泽阿恩埃免疫疗法股份有限公司 多表位构建体
WO2024002985A1 (en) 2022-06-26 2024-01-04 BioNTech SE Coronavirus vaccine
LU103079B1 (en) * 2023-02-28 2024-08-28 PMCR GmbH IMMUNIZATION AGAINST VIRAL INFECTIONS DISEASE(S)
WO2024123139A1 (ko) * 2022-12-09 2024-06-13 주식회사 나이벡 타겟 세포 내로 올리고뉴클레오티드를 전달하기 위한 펩타이드 기반 결합체를 포함하는 나노입자 및 이를 포함하는 약학적 조성물
JP2025541845A (ja) * 2022-12-09 2025-12-23 ソウル大学校産学協力団 Ｂ細胞及びＴ細胞内へｍＲＮＡを伝達するためのペプチド基盤結合体を含むナノ粒子及びこの用途
WO2024130254A2 (en) * 2022-12-16 2024-06-20 Geneius Biotechnology, Inc. A multi-antigenic rna sars-cov-2 vaccine and associated methods
PL443854A1 (pl) * 2023-02-22 2024-08-26 Instytut Immunologii I Terapii Doświadczalnej Polskiej Akademii Nauk Epitop pochodzący z białka N wirusa SARS-CoV-2, zawierający go antygen, ich zastosowania i sposób wykrywania choroby wywoływanej przez koronawirusa
EP4669348A1 (en) 2023-02-24 2025-12-31 BioNTech SE IMMUNOGENEOUS COMPOSITIONS
KR20250156726A (ko) * 2023-03-06 2025-11-03 백스톤 인코포레이티드 Covid-19 융합 단백질에 대한 뉴클레오캡시드 항원 면역 요법 및 사용 방법
WO2024263826A1 (en) * 2023-06-22 2024-12-26 Modernatx, Inc. Sars-cov-2 t cell vaccines
WO2025101631A2 (en) * 2023-11-07 2025-05-15 BioNTech SE Compositions and methods for preparing vaccines
TW202539697A (zh) 2023-11-15 2025-10-16 德商拜恩技術股份公司 冠狀病毒疫苗
GB202416789D0 (en) 2023-11-15 2025-01-01 BioNTech SE SARS-COV-2 immunogenic compositions
CN118955657B (zh) * 2024-01-09 2025-03-04 中山大学 一种特异性表位多肽及其试剂盒和应用
WO2025164815A1 (ko) * 2024-01-29 2025-08-07 주식회사 나이벡 안지오텐신전환효소 2(ace2)에 대한 결합능이 있는 신규한 펩타이드 및 이의 용도
CN119144611A (zh) * 2024-09-19 2024-12-17 宁夏农林科学院枸杞科学研究所 黑果枸杞LrCHS2基因及其编码蛋白在促进枸杞花青素生物合成中的应用
CN120081914A (zh) * 2025-01-03 2025-06-03 中国人民解放军军事科学院军事医学研究院 一种HLA-C限制性SARS-CoV-2淋巴细胞抗原表位肽及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005012337A2 (en) * 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
US20050106563A1 (en) * 2003-09-08 2005-05-19 Genesis Biotech Inc. Epitope profiles of SARS coronavirus
CN100408595C (zh) * 2003-12-31 2008-08-06 第二军医大学免疫学研究所 Sars病毒hla-a2限制性表位多肽及其应用
CN101085812B (zh) * 2006-06-08 2010-12-01 中国科学院上海生命科学研究院 一种sars冠状病毒多肽抗原及其应用
CN102227442B (zh) * 2008-11-28 2014-04-16 日油株式会社 Sars冠状病毒的细胞毒性t细胞表位肽及其用途
BR112014013745B1 (pt) * 2011-12-09 2022-06-14 Institut Pasteur Método de teste in vitro, kit de detecção e seu uso, método in vitro de diagnóstico, método de fabricação de kit, e teste de imunosseleção multiplex
WO2017013170A1 (en) * 2015-07-22 2017-01-26 F. Hoffmann-La Roche Ag Identification of antigen epitopes and immune sequences recognizing the antigens

Also Published As

Publication number Publication date
EP4121104A2 (en) 2023-01-25
TW202200199A (zh) 2022-01-01
US20230141371A1 (en) 2023-05-11
AU2021237720A1 (en) 2022-11-17
BR112022018819A2 (pt) 2022-11-29
IL296617A (en) 2022-11-01
CA3172315A1 (en) 2021-09-23
KR20230004508A (ko) 2023-01-06
US20230083931A1 (en) 2023-03-16
WO2021188969A3 (en) 2021-11-25
EP4121104A4 (en) 2025-12-17
WO2021188969A2 (en) 2021-09-23
JP2023518821A (ja) 2023-05-08

Similar Documents

Publication Publication Date Title
MX2022011671A (es) Vacunas contra el coronavirus y metodos de uso.
MX2022014561A (es) Inhibidores de mek para el tratamiento o prevencion de infecciones por coronavirus y/o tormenta de citocinas por covid-19.
DOP2023000187A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
MX2019009443A (es) Metodos para tratar la influenza.
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
WO2022217155A3 (en) Thionucleosides as antiviral agents
CL2007001392A1 (es) Compuestos derivados de quinolina o benzopirano inhibidores de la replicacion del hiv; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una infeccion por vih
CL2008003406A1 (es) Compuestos derivados de quinolina; composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vih.
ECSP099447A (es) Derivados indólicos con anillo unido en las posiciones 4,5 y sus métodos de uso
MX2019002678A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
CR20240363A (es) Compuestos y métodos para el tratamiento de infecciones virales.
BR0316346A (pt) Vacina para vìrus do nilo ocidental
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
MX2022007908A (es) Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv.
CO2022012272A2 (es) Vacunas contra el coronavirus y métodos de uso
MX2017003117A (es) Particula tipo virus de flavivirus.
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.
MX2023003199A (es) Vacuna contra la enfermedad por coronavirus de 2019 (covid-19) basada en el virus de la parainfluenza 5 (piv5).
CL2007001826A1 (es) Compuestos derivados de 2-(amino-sustituido)-benzotiazol-sulfonamida, inhibidores de proteasa, en particular, inhibidores de proteasa de vih; composicion farmaceutica; y uso para tratar o combatir una infeccion o enfermedad asociada con la infeccion de un retrovirus resistente a multiples farmacos.
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
CL2007002710A1 (es) Formulacion inmunogenica que confiere proteccion contra la infeccion o patologia causada por el virus respiratorio sincicial (vrs) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulacion inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del vrs.
AR056733A1 (es) Uso de vacunas para el tratamiento / prevencion de la transmision de patogenos
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma